What does this research mean for the field?

A dual time window-driven strategy targeting alkaline phosphatase normalization improves treatment optimization and risk stratification for primary biliary cholangitis compared to the standard ≤1.67 × ULN criterion. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

The aim is to enhance management of primary biliary cholangitis by focusing on alkaline phosphatase normalization and early intervention.

May 17, 2026Journal of Clinical and Translational Hepatology0 citationsOpen Access

A Dual Time Window-driven Strategy to Optimize Primary Biliary Cholangitis Treatment via Alkaline Phosphatase Normalization

HZHan Zhao YLYansheng Liu YTYingmei TangYunnan University

Key Points

The aim is to enhance management of primary biliary cholangitis by focusing on alkaline phosphatase normalization and early intervention.
Establishing alkaline phosphatase normalization as a key treatment target.
Identifying optimal early intervention windows for treatment.
Developing risk stratification criteria for patient management.
Emphasizing the importance of achieving ALP normalization in treatment plans.
Recognizing that some patients achieving current biochemical response criteria may still face liver complications.
Creating a framework for better risk assessment in treatment strategies.

Abstract

The current criterion of biochemical response to ursodeoxycholic acid in primary biliary cholangitis is an alkaline phosphatase (ALP) level of ≤1.67 × the upper limit of normal (ULN) after 12 months of treatment. However, a proportion of patients who meet this parameter may still progress to liver decompensation. This study aimed to optimize the clinical management of primary biliary cholangitis by (1) establishing ALP normalization as a core treatment target, (2) identifying early intervention windows, and (3) developing risk stratification criteria.

AIに質問

Bookmark

View Full Paper